The company's financial position appears highly vulnerable, with a current ratio of 0.16 and a heavy reliance on $29.7M of goodwill rather than liquid assets.
| Total Current Assets | 2.92M | 2.82M | 455.4K | 22.63K | 3.51K | 4.76K | 62.65K |
| Cash & Short-Term Investments | 1.57M | 1.7M | 66.14K | 15.42K | 2.24K | 4.76K | 62.65K |
| Cash Only | 1.57M | 1.7M | 66.14K | 15.42K | 2.24K | 4.76K | 62.65K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 526.26K | 599.07K | 0 | 0 | 402 | 0 | 0 |
| Days Sales Outstanding | 83.68 | 75.25 | - | - | - | - | - |
| Inventory | 462.45K | 196.43K | 0 | 0 | 858 | 0 | 0 |
| Days Inventory Outstanding | 21.29 | 31 | - | - | - | - | - |
| Other Current Assets | 52.86K | 0 | 389.26K | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 169.26M | 168.42M | 1.85M | 36.61M | 92.47K | 700.33K | 260.1K |
| Property, Plant & Equipment | 200.26K | 252.17K | 0 | 0 | 295 | 0 | 0 |
| Fixed Asset Turnover | 18.59x | 11.52x | - | - | - | - | - |
| Goodwill | 29.73M | 24.95M | 0 | 0 | 9.64K | 0 | 0 |
| Intangible Assets | 138.97M | 142.46M | 0 | 0 | 82.33K | 0 | 0 |
| Long-Term Investments | 643.43K | 1.11K | 1.85M | 36.61M | 4 | 0 | 0 |
| Other Non-Current Assets | 46.74K | 555.19K | 0 | 0 | 174 | 700.33K | 260.1K |
| Total Assets | 172.19M | 171.24M | 2.3M | 36.63M | 95.98K | 705.09K | 322.75K |
| Asset Turnover | 0.01x | 0.02x | 1.53x | - | - | - | - |
| Asset Growth % | 8879.8% | 7335.31% | -93.71% | 38061.04% | -86.39% | 118.46% | - |
| Total Current Liabilities | 17.9M | 17.17M | 6.72M | 2.04M | 4.66K | 707.21K | 321.56K |
| Accounts Payable | 8.26M | 7.83M | 0 | 0 | 3.38K | 2.85K | 0 |
| Days Payables Outstanding | 639.29 | 1.24K | - | - | - | - | - |
| Short-Term Debt | 4.67M | 4.34M | 1.76M | 0 | 904 | 400K | 300K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.48M | 3.5M | 4.96M | 1.51M | 83 | 0 | 0 |
| Current Ratio | 0.16x | 0.16x | 0.07x | 0.01x | 0.75x | 0.01x | 0.19x |
| Quick Ratio | 0.14x | 0.15x | 0.07x | 0.01x | 0.57x | 0.01x | 0.19x |
| Cash Conversion Cycle | -534.32 | -1.13K | - | - | - | - | - |
| Total Non-Current Liabilities | 26.9M | 27.04M | 2.07M | 2.07M | 12.56K | 0 | 0 |
| Long-Term Debt | 272.91K | 0 | 0 | 0 | 101 | 0 | 0 |
| Capital Lease Obligations | 52.66K | 12.55K | 0 | 0 | 196 | 0 | 0 |
| Deferred Tax Liabilities | 112.04M | 27.02M | 0 | 0 | 12.26K | 0 | 0 |
| Other Non-Current Liabilities | 66.54K | 1.7K | 2.07M | 2.07M | 0 | 0 | 0 |
| Total Liabilities | 44.8M | 44.2M | 8.79M | 4.11M | 17.22K | 707.21K | 321.56K |
| Total Debt | 4.95M | 4.4M | 1.76M | 0 | 1.24K | 400K | 300K |
| Net Debt | 3.39M | 2.7M | 1.7M | -15.42K | -998 | 395.24K | 237.35K |
| Debt / Equity | 0.04x | 0.03x | - | - | 0.02x | - | 252.53x |
| Debt / EBITDA | -0.51x | - | - | - | 0.01x | 1.71x | 1.64x |
| Net Debt / EBITDA | -0.35x | - | - | -0.02x | -0.01x | 1.69x | 1.30x |
| Interest Coverage | -39.76x | -56.07x | -275.31x | - | - | - | - |
| Total Equity | 127.39M | 127.04M | -6.49M | 32.52M | 78.77K | -2.12K | 1.19K |
| Equity Growth % | 3673.3% | 2058.71% | -119.94% | 41186.17% | 3815.38% | -278.45% | - |
| Book Value per Share | 28.42 | 28.34 | -1.45 | 4.21 | 0.01 | -0.00 | 0.00 |
| Total Shareholders' Equity | 103.86M | 77.64M | -6.49M | 32.52M | 78.77K | -2.12K | 1.19K |
| Common Stock | 3.33K | 2.66K | 1.85M | 36.43M | 3.65K | 173 | 173 |
| Retained Earnings | -40.1M | -37.17M | -8.33M | -3.91M | 42 | -27.12K | -23.81K |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.66M | 3.84M | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 23.53M | 49.4M | 0 | 0 | 0 | 0 | 0 |
Imminent liquidity depletion risk
As reported in financial statements, OSRH's total assets have stagnated near $172M while equity has fluctuated significantly, suggesting that the company's transition from a blank check entity has failed to build a stable capital base capable of supporting its ongoing clinical development and administrative overhead requirements.
The trajectory of the balance sheet indicates a lack of organic growth, with equity volatility reflecting the challenges of integrating acquired assets. Investors should monitor whether the current asset base can be leveraged effectively or if further dilution is inevitable to maintain operations.
Based on reported figures, OSRH's asset mix is heavily weighted toward goodwill, which reached $29.7M in 2026Q1, indicating that the company's valuation is largely tied to intangible acquisition premiums rather than tangible infrastructure or productive assets necessary for long-term biotechnology research and development.
The minimal investment in net PPE, totaling only $200.3K, suggests an asset-light model that may lack the internal laboratory capabilities required for independent clinical advancement. This reliance on intangible assets warrants further investigation into the recoverability of these values should clinical milestones fail to materialize.
According to recent SEC filings, OSRH's current ratio has plummeted to 0.16 as of 2026Q1, reflecting a severe inability to cover short-term liabilities with existing cash reserves of only $1.6M, which appears insufficient to sustain the company's high-burn operating model for more than a few quarters.
The persistent decline in liquidity metrics suggests that the company is operating with virtually no buffer against operational shocks or clinical delays. This precarious position implies that management may be forced to seek emergency financing, which could lead to significant shareholder dilution.
As indicated by the company's balance sheet, the accumulation of $29.7M in goodwill following the merger represents a significant risk, as any failure to validate the acquired oncology and ophthalmology intellectual property could trigger substantial impairment charges that would further erode the company's already fragile equity position.
The presence of such high goodwill relative to total equity suggests that the market's perception of the company's value is highly sensitive to the success of its pipeline. Investors should be wary that these intangible assets may not provide any tangible support if the company's clinical strategy falters.
Quick answers to the most common questions about buying OSRH stock.
As of 2025, OSR Holdings, Inc. (OSRH) had total assets of $171.2M including $2.8M in current assets.
OSR Holdings, Inc. (OSRH) carries total debt of $4.4M, offset by $1.7M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
OSR Holdings, Inc. (OSRH) has total shareholders' equity (book value) of $77.6M ($28.34 book value per share). Book value represents the net worth of the company belonging to common stock holders.
OSR Holdings, Inc. (OSRH) reported a current ratio of 0.16x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.